


## Levomefolate calcium pentahydrate

### Chemical Properties

CAS No. : 419563-18-1  
 Formula: C<sub>20</sub>H<sub>33</sub>CaN<sub>7</sub>O<sub>11</sub>  
 Molecular Weight: 587.59  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



### Biological Description

|               |  |
|---------------|--|
| Description   | Levomefolate calcium pentahydrate is the calcium salt of 5-methyltetrahydrofolic acid, a biologically active form of folic acid that functions, in conjunction with Vitamin B12. Levomefolate is included in formulations of certain oral contraceptives to ensure adequate folic acid levels in women of child-bearing age to reduce the risk of neural tube defects. |
| Targets(IC50) | Others   |

### Preparing Stock Solutions

|       | 1mg       | 5mg       | 10mg       |
|-------|-----------|-----------|------------|
| 1 mM  | 1.7019 mL | 8.5093 mL | 17.0187 mL |
| 5 mM  | 0.3404 mL | 1.7019 mL | 3.4037 mL  |
| 10 mM | 0.1702 mL | 0.8509 mL | 1.7019 mL  |
| 50 mM | 0.034 mL  | 0.1702 mL | 0.3404 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. *J Clin Psychiatry*. 2015 Dec;76(12):1635-41. doi: 10.4088/JCP.14m09587. PubMed PMID: 26613389.

Diefenbach K, Trummer D, Ebert F, Lissy M, Koch M, Rohde B, Blode H. EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation. *Int J Womens Health*. 2013 Apr 11;5:149-63. doi: 10.2147/IJWH.S37254. Print 2013. PubMed PMID: 23610531; PubMed Central PMCID: PMC3628530.

Nelson AL. Comprehensive evaluation of Safyral(®) 2012. *Womens Health (Lond)*. 2012 Nov;8(6):619-33. doi: 10.2217/whe.12.50. Review. PubMed PMID: 23181528.

Wiesinger H, Eydeler U, Richard F, Trummer D, Blode H, Rohde B, Diefenbach K. Bioequivalence evaluation of a folate-supplemented oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium versus ethinylestradiol/drospirenone and levomefolate calcium alone. *Clin Drug Investig*. 2012 Oct 1;32(10):673-84. doi: 10.2165/11635280-000000000-00000. PubMed PMID: 22909145.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481